Immune checkpoint inhibitor therapy for breast cancer

Abstract

Breast cancer is a common malignancy among women, with a reported incidence rate of 7-10% among all types of malignant tumors. Heredity frequently contributes to its incidence, and the prevalence typically increases with age, peaking in women between the ages of 40 and 60. Immune checkpoint inhibitors are a type of molecule that can activate the immune cells to enhance the host immune system to fight cancer. With these inhibitors, immune checkpoint inhibitor therapy (ICIT) aims to block the inhibitory signal of immune cell activation by antibodies or chemicals to promote an anti-tumor immune response, which lets immune cells recognize and kill cancer cells more effectively. This article offers crucial insights into immune checkpoint inhibitor therapy, outlining its principles and diverse applications.Moreover, it delves into the findings derived from pre­vious clinical trials of immune checkpoint inhibitors, analyzing the collected data. Specifically, the article will extensively examine the role of immune checkpoint in­hibitor therapy in the context of breast cancer treatment. By summarizing existing examples of immune checkpoint inhibitor therapy and their outcomes, the article aims to evaluate the feasibility of employing this therapeutic ap­proach in breast cancer treatment.